RNAC compared with LLY: revenue, margins and what each company keeps, and the suppliers and customers both name

RNACCartesian Therapeutics, Inc.

Mkt capRevenueRevenue

LLYELI Lilly & Co

Mkt capRevenueRevenue

Compare

RNACCartesian Therapeutics, Inc.

LLYELI Lilly & Co

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

RNAC

1 of 3at or beyond implied

Reportimpliedrealized× implied

Q3 FY26—▼−0.59%—

Q2 FY26±16.9%▲+4.91%×0.29

Apr 30 '26±52.8%▼−3.86%×0.07

Q1 FY26±31.0%▲+31.68%×1.02

LLY

3 of 4at or beyond implied

Reportimpliedrealized× implied

Q3 FY26±5.1%▲+6.63%×1.29

Q2 FY26±6.2%▲+4.86%×0.79

= impliedRNAC realized, solidLLY realized, hatchedOne scale, both sides: full bar = 53%× = |realized| ÷ impliedSource: market data

Q1 FY26

±5.3%

▲+9.80%

×1.85

Feb 4 '26±6.1%▲+10.33%×1.69

RNACCartesian Therapeutics, Inc.

7.57▲+11.68%· post 7.57

Mkt cap$229.7MRevenue$78,000Q1 FY26Revenue$3MFY25

LLYELI Lilly & Co

1,360.90▼−0.28%· post 1,358.90

ClosedNov 6 '26

Mkt cap$1.2TRevenue$24.4BQ3 FY26Revenue$65.2BFY25

Compare

ClosedNov 6 '26

RNACCartesian Therapeutics, Inc.

LLYELI Lilly & Co

7.57▲+11.68%post 7.57

Price

1,360.90▼−0.28%post 1,358.90

$229.7M

Mkt cap

$1.2T

Q1 FY26$78,000

Revenue

$24.4BQ3 FY26

FY25$3M

Revenue

$65.2BFY25

RNAC7.57▲+11.68%vsLLY1,360.90▼−0.28%ClosedNov 6 '26